Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 ...

Eisai has already reached settlement agreements with two other companies seeking to market Lenvima generics in the US – Sun ...

The second batch of Commissioner's national priority vouchers (CNPVs) has been published by the FDA, and includes new GLP-1 agonists for weight-loss from Eli Lilly and Novo Nordisk and drugs for ...

According to the White House, Novo Nordisk's semaglutide-based Ozempic for diabetes and Wegovy for obesity will cost $350 per ...

HES can provide the kind of real-world evidence that some life sciences companies have a great deal of difficulty in ...

The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...

Eli Lilly has raised the stakes in the obesity market with midstage data for an amylin-targeting drug, eloralintide, that ...

AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...

The new data from the OASIS 4 trial of Novo Nordisk's 25 mg oral formulation of semaglutide included an indirect comparison ...

Pfizer – which first agreed a $4.9 billion takeover deal with Metsera in September – has argued that the rival bid is ...

Although rare kidney diseases remain a significantly overlooked contributor to the global burden of CKD, things have begun to ...